In NB-1 cells, ZSET-845 has no inhibitory action on AChE activity and enhances choline acetyltransferase (ChAT) activity[1].

ZSET-845 at the dose of 0.01, 0.1 and 1 mg/kg significantly ameliorates impaired performance caused by scopolamine.In the hippocampus, ZSET-845(Oral administration) causes an increase in ChAT activity . In the hippocampus, ZSET-845 (0.01, 0.1 or 1 mg/kg) significantly increases ChAT activity (112%, 113.8% or 108.7%, respectively) compared with matched vehicle-injected control rats[1]. Oral administration of ZSET845 at a dose of 1 or 10 mg/kg ameliorates learning impairment in passive avoidance task and enhanced ChAT activity in the basal forebrain, medial septum and hippocampus, and increases in the number of ChAT-immunoreactive cells in the medial septum in Ab-treated rats to the levels of vehicle-injected control rats[2].

324077-62-5

C21H18N2O

314.38

ZSET-845

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years